Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2017 | short review

Milestones in advanced renal cell carcinoma

verfasst von: Dora Niedersuess-Beke

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Summary

Renal cell carcinoma (RCC) is a common tumor that is largely refractory to cytotoxic agents. With the implementation of a multitude of novel therapies in the past 10 years, the overall survival of patients with advanced RCC has more than doubled.
Vorheriger Artikel Milestones in gastric cancer
Nächster Artikel Milestones in pathology—from histology to molecular biology
Literatur
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Kroeger N, Choueiri T, Lee J, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014;65:1086–92.CrossRefPubMed
3.
Baldewijns M, Van Vlodrop I, Vermeulen P, et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221:125–38.CrossRefPubMed
4.
Klatte T, Pantuck A. Molecular biology of renal cortical tumors. Urol Clin North Am. 2008;35:573–80.CrossRefPubMed
5.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.CrossRefPubMed
6.
Lee J, Kim M, Park I, et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26:2300–5.CrossRefPubMed
7.
Rini B, Wood L, Elson P, et al. A phase II study of intermittent sunitinib (S) in previously untreated patients (Pts) with metastatic renal cell carcinoma (mRCC). ASCO Annual Meeting. J Clin Oncol. 2013;31(Suppl; abstr 4515).
8.
Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal cell carcinoma. N Engl J Med. 2013;369:722–31.CrossRefPubMed
9.
Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32:1412–8.CrossRefPubMed
10.
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–34.CrossRefPubMed
11.
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.CrossRefPubMed
12.
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11.CrossRefPubMed
13.
14.
15.
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81.CrossRefPubMed
16.
Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.CrossRefPubMed
17.
Grullich C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 2014;201:207–14.CrossRefPubMed
18.
Zhou L, Liu X, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687–97.CrossRefPubMed
19.
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, openlabel, phase 3 trial. Lancet Oncol. 2016;17:917–27.CrossRefPubMed
20.
Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–v68.CrossRefPubMed
21.
Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–82.CrossRefPubMed
22.
Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and metaanalysis. Eur Urol. 2015;67:740–9.CrossRefPubMed
23.
Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomisedphase 2 trial. Lancet Oncol. 2016;17:378–88.CrossRefPubMed
24.
Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.CrossRefPubMed
25.
Ravaud A, Motzer R, Pandha H, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246–54.CrossRefPubMed
26.
Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008–16.CrossRefPubMed
27.
Fyfe GA, Fisher RI, Rosenberg SA, et al. Long term response data for 255 patients with metastatic renal cell carcinoma treated with high dose recombinant interleukin 2 therapy. J Clin Oncol. 1996;14:2410–1.CrossRefPubMed
28.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advancedrenal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefPubMed
29.
Metadaten
Titel
Milestones in advanced renal cell carcinoma
verfasst von
Dora Niedersuess-Beke
Publikationsdatum
01.02.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0321-9

Weitere Artikel der Ausgabe 1/2017

Milestones in myeloma

  • short review

Milestones in Chronic Lymphocytic Leukemia

  • Open Access
  • short review

My personal highlights of ESMO 2016

  • Open Access
  • comment

Milestones of the last 10 years

  • Open Access
  • short review

Milestones in gastric cancer

  • short review

memo: Official journal of the OeGHO and CECOG

  • editorial